Back to Search Start Over

Chronic exposure to E-cigarette aerosols potentiates atherosclerosis in a sex-dependent manner.

Authors :
Caruana V
Giles BH
Kukolj N
Juran R
Baglole CJ
Mann KK
Source :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2024 Sep 06; Vol. 492, pp. 117095. Date of Electronic Publication: 2024 Sep 06.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Despite being designed for smoking cessation, e-cigarettes and their variety of flavors have become increasingly attractive to teens and young adults. This trend has fueled concerns regarding the potential role of e-cigarettes in advancing chronic diseases, notably those affecting the cardiovascular system. E-cigarettes contain a mixture of metals and chemical compounds, some of which have been implicated in cardiovascular diseases like atherosclerosis. Our laboratory has optimized in vivo exposure regimens to mimic human vaping patterns. Using these established protocols in an inducible (AAV-PCSK9) hyperlipidemic mouse model, this study tests the hypothesis that a chronic exposure to e-cigarette aerosols will increase atherosclerotic plaques. The exposures were conducted using the SCIREQ InExpose™ nose-only inhalation system and STLTH or Vuse products for 16 weeks. We observed that only male mice exposed to STLTH or Vuse aerosols had significantly increased plasma total cholesterol, triglycerides, and LDL cholesterol levels compared to mice exposed to system air. Moreover, these male mice also had a significant increase in aortic and sinus plaque area. Male mice exposed to e-cigarette aerosol had a significant reduction in weight gain over the exposure period. Our data indicate that e-cigarette use in young hyperlipidemic male mice increases atherosclerosis in the absence of significant pulmonary and systemic inflammation. These results underscore the need for extensive research to unravel the long-term health effects of e-cigarettes.<br />Competing Interests: Declaration of competing interest The authors declare they have no conflicts of interest related to this work to disclose.<br /> (Copyright © 2024. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1096-0333
Volume :
492
Database :
MEDLINE
Journal :
Toxicology and applied pharmacology
Publication Type :
Academic Journal
Accession number :
39245079
Full Text :
https://doi.org/10.1016/j.taap.2024.117095